Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (LSE:0A4C) with a Market Perform recommendation. There are 326 funds or institutions reporting positions in ...

William Blair started coverage on shares of Altimmune in a research note on Friday. They issued a “market perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $ ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

William Blair Global Leaders Fund earns a Below Average Process Pillar rating. The process is bolstered by low costs across its parent firm's funds, whose fees rank in their respective category's ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever This table compares Li-Cycle and Decent’s net margins, return on equity and ...

The Fund seeks long-term capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of equity securities, including common ...